Thatch Hits $1 Billion Valuation as Healthcare Costs Surge
Thatch raises $108 million at a $1 billion valuation after sevenfold ARR growth as 2027 employer healthcare costs rise over 8%, the highest since 2003.
Summary
Thatch raised $108 million at a $1 billion valuation on September 15, 2026, from existing investors The General Partnership, Index Ventures, General Catalyst and Andreessen Horowitz. The financing comes 17 months after a $40 million Series B valued it at $410 million, PitchBook data shows. CEO Chris Ellis says annual recurring revenue grew about sevenfold. Ellis founded Thatch in 2021 with former Stripe engineering executive Adam Stevenson. The valuation leap is notable because Thatch is not primarily an AI startup.
Employer healthcare expenses are projected to rise more than 8% in 2027, the largest increase since 2003, while traditional plans rarely cover increasingly popular GLP-1 drugs such as Ozempic and Wegovy. Thatch uses ICHRA, created by federal regulation in 2020 and recently rebranded CHOICE, to replace company-wide plans negotiated with carriers such as Anthem or United Healthcare. Employers provide fixed, pre-tax budgets, and workers choose among dozens of health, dental and vision plans, aided by Thatch’s AI recommendations. Employees needing extensive care can pay extra for broader coverage, while healthier workers can spend leftover funds through a Thatch debit card on eligible expenses including GLP-1s or an Oura Ring. Ellis says employers avoid annual carrier negotiations while maintaining similar coverage, often at slightly lower cost, and workers can switch insurers, encouraging better service and fewer denied claims. Rivals include Take Command, Remodel Health and Zorro.
Positives
- $108 million from four existing investors lifted Thatch’s valuation to $1 billion just 17 months after its $410 million Series B valuation.
- Sevenfold annual recurring revenue growth signals rapid employer adoption of Thatch’s healthcare benefits platform.
- Dozens of health, dental and vision plans give workers more choice than a single company-wide policy.
- Fixed, pre-tax budgets can spare employers annual carrier negotiations while providing similar coverage at slightly lower cost.
- Unused allowances can fund eligible GLP-1 drugs or an Oura Ring through the Thatch debit card.
Risks & concerns
- Employer healthcare expenses are projected to rise more than 8% in 2027, the largest increase since 2003.
- Traditional health plans rarely cover increasingly sought GLP-1 treatments such as Ozempic and Wegovy.
- Workers requiring extensive care may need out-of-pocket contributions beyond their employer-funded allowance.
- Take Command, Remodel Health and Zorro are competing for employers adopting the same federally enabled benefits model.